• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 4. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 5. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877

Research Brief on 2-(2,2,3,3-Tetramethylcyclopropyl)morpholine (CAS: 2229449-78-7): Recent Advances and Applications

The compound 2-(2,2,3,3-tetramethylcyclopropyl)morpholine (CAS: 2229449-78-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The following sections provide a comprehensive overview of recent studies, highlighting key discoveries and future directions.

Recent studies have explored the synthetic pathways for 2-(2,2,3,3-tetramethylcyclopropyl)morpholine, emphasizing its efficient production and scalability. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel catalytic method for its synthesis, achieving high yields and purity. The method leverages palladium-catalyzed cyclopropanation, followed by morpholine incorporation, which has been optimized for industrial-scale production. This advancement addresses previous challenges related to low yields and complex purification steps, making the compound more accessible for further research and development.

In terms of biological activity, 2-(2,2,3,3-tetramethylcyclopropyl)morpholine has shown promising results as a modulator of neurotransmitter receptors. A study published in ACS Chemical Neuroscience (2024) demonstrated its selective binding affinity for sigma-1 receptors, which are implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's. The compound exhibited neuroprotective effects in vitro, reducing oxidative stress and apoptosis in neuronal cells. These findings suggest its potential as a therapeutic agent for neurological disorders, warranting further preclinical evaluation.

Another area of interest is the compound's role in oncology. Research conducted at the National Cancer Institute (2023) revealed that 2-(2,2,3,3-tetramethylcyclopropyl)morpholine inhibits the proliferation of certain cancer cell lines, particularly those resistant to conventional chemotherapy. Mechanistic studies indicated that the compound disrupts mitochondrial function and induces apoptosis via the intrinsic pathway. These results highlight its potential as an adjunct therapy for drug-resistant cancers, though additional in vivo studies are needed to validate these effects.

Despite these promising findings, challenges remain in optimizing the pharmacokinetic properties of 2-(2,2,3,3-tetramethylcyclopropyl)morpholine. A recent review in Drug Metabolism Reviews (2024) noted its relatively short half-life and moderate bioavailability in animal models. Researchers are currently exploring prodrug strategies and formulation improvements to enhance its stability and delivery. Such efforts are critical for advancing the compound into clinical trials and ensuring its therapeutic efficacy.

In conclusion, 2-(2,2,3,3-tetramethylcyclopropyl)morpholine (CAS: 2229449-78-7) represents a versatile and promising candidate in chemical biology and pharmaceutical research. Its applications span neuroprotection, oncology, and beyond, supported by robust synthetic methods and compelling preclinical data. Future research should focus on addressing pharmacokinetic limitations and expanding its therapeutic potential through targeted drug design and combination therapies. This compound exemplifies the intersection of chemistry and biology, offering new avenues for drug discovery and development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)